Drugs Containing Excipient (Inactive Ingredient) SODIUM PHOSPHATE P-32

« Back to Dashboard

Branded drugs containing SODIUM PHOSPHATE P-32 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Solubiomix LLC	QUIOFIC	folic acid	69499-501	SODIUM PHOSPHATE P-32

Generic drugs containing SODIUM PHOSPHATE P-32 excipient

Company	Ingredient	NDC	Excipient
Solubiomix LLC	folic acid	69499-501	SODIUM PHOSPHATE P-32

Sodium Phosphate P-32 Market Dynamics, Regulatory Status, and Financial Trajectory

Last updated: October 15, 2026

Sodium phosphate P-32 is a therapeutic radiopharmaceutical, not a pharmaceutical excipient. Its commercial market is small, specialized, and difficult to measure because product-level sales are rarely disclosed. Demand has declined in hematology as hydroxyurea, interferon, ruxolitinib, and other systemic therapies have replaced radioactive phosphorus in many treatment pathways. The product retains a limited role where low acquisition cost, single-dose administration, and long clinical experience outweigh marrow-toxicity and radiation-handling constraints.

What is sodium phosphate P-32 used for?

Sodium phosphate P-32 is a radiolabeled inorganic phosphate administered as a therapeutic beta-emitting drug. Phosphorus-32 has a physical half-life of approximately 14.3 days and emits high-energy beta particles without a significant gamma component, supporting therapeutic use while creating substantial radiation-safety and waste-management requirements.[1]

Historically, physicians used P-32 sodium phosphate for:

• Polycythemia vera
• Essential thrombocythemia
• Selected myeloproliferative disorders
• Palliative treatment of certain hematologic conditions
• Certain bone and blood disorders requiring marrow suppression

Its principal therapeutic effect is irradiation of proliferating marrow cells. The same mechanism creates the product’s main clinical limitation: delayed and potentially irreversible myelosuppression, including risk of acute leukemia and marrow failure.

The product is therefore more accurately classified as an old-line therapeutic radiopharmaceutical than as an excipient, specialty ingredient, or conventional phosphate salt.

How large is the sodium phosphate P-32 market?

No reliable public source provides a standalone global market size or audited revenue series for sodium phosphate P-32. The market is generally embedded within broader categories such as therapeutic radiopharmaceuticals, radiopharmacy products, or hematology medicines.

The commercial market is likely small for five structural reasons:

Market factor	Effect on sodium phosphate P-32
Narrow indication base	Limits annual patient volume
Generic or legacy-product economics	Restricts pricing power
Competition from systemic therapies	Reduces use in myeloproliferative neoplasms
Short isotope half-life	Raises distribution and inventory costs
Specialized administration	Concentrates demand in licensed nuclear-medicine centers

P-32 does not participate in the high-growth segment of radiopharmaceuticals associated with targeted alpha therapy, lutetium-177, or actinium-225. Those products are supported by oncology pipelines, companion diagnostics, and premium pricing. Sodium phosphate P-32 is generally an established, low-cost product with limited patent leverage.

What drives demand for sodium phosphate P-32?

Demand depends on four variables:

1. The size of the remaining patient population with a suitable indication.
2. Physician preference in older or treatment-refractory patients.
3. Availability of competing cytoreductive therapies.
4. Access to licensed radiopharmacy infrastructure.

Use is more likely in patients who are older, have limited treatment options, or require a durable cytoreductive response but are not candidates for newer or more intensive treatment. Use is less likely in younger patients because of cumulative marrow toxicity and concern over therapy-related malignancy.

How does sodium phosphate P-32 compare with competing treatments?

The competitive position of P-32 is strongest on acquisition cost and dosing simplicity. It is weakest on long-term safety, reversibility, and suitability for younger patients.

Treatment	Primary role	Relative strengths	Relative weaknesses
Sodium phosphate P-32	Legacy cytoreductive therapy	Low cost, single administration, long clinical history	Delayed marrow toxicity, leukemogenic concern, radiation handling
Hydroxyurea	First-line cytoreduction in many patients	Oral, familiar, adjustable	Chronic dosing, intolerance, resistance
Pegylated interferon	Cytoreduction, especially in selected younger patients	Disease-control potential, non-leukemogenic profile relative to P-32	Injection burden, tolerability, cost
Ruxolitinib	Polycythemia vera and myelofibrosis settings	Symptom control and targeted mechanism	High cost, infection risk, chronic treatment
Busulfan	Later-line cytoreduction	Oral administration, useful in selected older patients	Myelosuppression and secondary-malignancy concerns
Radioisotope alternatives	Selected hematologic or oncologic uses	Therapeutic radiation without conventional chemotherapy	Limited indications and infrastructure

Clinical guidelines generally place P-32 outside the preferred first-line treatment position for most contemporary patients with polycythemia vera or essential thrombocythemia. Its residual market is concentrated in carefully selected cases rather than broad population treatment.[2][3]

What is the FDA regulatory status of sodium phosphate P-32?

Sodium phosphate P-32 has a legacy regulatory history in the United States. FDA and DailyMed records should be distinguished from current commercial availability. A product can retain historical labeling or an established NDA record while being unavailable, intermittently supplied, or discontinued in practice.

The relevant regulatory characteristics are:

• It is a therapeutic radiopharmaceutical, not an excipient.
• It requires radioactive-material licensing and handling controls.
• It is administered under medical supervision.
• It has product-specific dosage, radiation-safety, and storage requirements.
• It is not a biologic and therefore has no biosimilar pathway.
• Generic substitution is constrained by isotope supply, dosage calibration, formulation, and radiopharmacy logistics.

The product’s regulatory value is primarily in its established clinical and manufacturing history. It does not have the regulatory profile of a newly approved precision radiopharmaceutical with an active clinical-development program.

Is sodium phosphate P-32 listed in the Orange Book?

Orange Book treatment depends on the specific product, NDA, and current marketing status. An historical NDA listing does not establish that an actively marketed product remains available. Conventional patent-driven Orange Book protection is not the principal commercial issue for P-32 sodium phosphate.

The more important barriers are:

• Radioisotope production and procurement
• Licensed handling facilities
• Radiopharmaceutical manufacturing controls
• Product-specific quality testing
• Distribution within the isotope half-life
• Compliance with federal and state radiation rules

These barriers can protect a supplier commercially even when no meaningful patent estate exists.

What patents protect sodium phosphate P-32?

The active ingredient itself is an old radioactive phosphate compound and is unlikely to have meaningful composition-of-matter patent protection. Any historical composition patents would be expired by now.

Potentially relevant intellectual-property categories include:

• Formulation and stabilizer patents
• Container and shielding systems
• Dose-calibration methods
• Radiopharmacy preparation methods
• Automated dispensing systems
• Manufacturing or purification methods
• New therapeutic uses
• Combination treatments

For a legacy sodium phosphate P-32 product, these categories generally offer limited exclusionary value. A formulation patent would need to cover a commercially material improvement, such as stability, radiochemical purity, administration, or waste reduction. A method-of-use patent would face narrow patient-selection and prior-art constraints.

Unlike modern radioligand therapies, P-32 sodium phosphate does not appear to have a commercially important patent estate supporting premium pricing or long market exclusivity.

When does sodium phosphate P-32 lose exclusivity?

The relevant exclusivity is effectively historical rather than prospective. The compound has been used clinically for decades, and any ordinary composition-of-matter protection has long expired.

A supplier’s competitive position is more likely to depend on:

• Active product registration
• Reliable isotope sourcing
• Manufacturing authorization
• Nuclear pharmacy distribution
• Institutional purchasing contracts
• Physician familiarity
• Ability to deliver calibrated doses on schedule

A new entrant could face operational barriers without encountering a blocking patent. This creates a market structure in which regulatory and manufacturing know-how replace patent exclusivity.

What manufacturing and supply-chain barriers affect P-32?

The short half-life creates a different economic model from conventional pharmaceuticals. Inventory cannot be held indefinitely. Manufacturers and radiopharmacies must coordinate isotope production, synthesis, quality release, shipment, administration, and disposal.

Key manufacturing constraints

Phosphorus-32 is produced through nuclear reactions and requires access to an appropriate reactor or isotope-production network. The supply chain must maintain:

• Stable isotope availability
• GMP-compliant processing
• Radiochemical purity
• Sterility and endotoxin control
• Accurate activity measurement
• Radiation shielding
• Licensed transport
• Secure radioactive waste management

The product is usually distributed according to activity and administration date rather than simple package volume. Shipping delays can reduce usable activity and cause treatment cancellations.

These requirements create a high fixed-cost, low-volume business. A manufacturer cannot rely on ordinary pharmaceutical scale economics. The commercial advantage belongs to suppliers with existing radiopharmacy infrastructure and a broader portfolio of radioisotopes.

What is the financial trajectory for sodium phosphate P-32?

The financial trajectory is likely mature to declining, with occasional stability in low-cost or underserved markets.

Period	Financial outlook	Main drivers
Historical peak	Established specialty demand	Limited alternatives and broad use in marrow disorders
Transition period	Declining utilization	Adoption of hydroxyurea, interferon, targeted therapies
Current market	Niche and fragmented	Older patients, treatment-refractory use, regional access
Long term	Low-growth or declining	Clinical substitution and aging product economics

Revenue exposure for any supplier is unlikely to be material at the company level unless the supplier has a very small or highly specialized portfolio. Public companies typically do not disclose sodium phosphate P-32 revenue separately. Sales are more likely reported within nuclear medicine, radiopharmaceuticals, or specialty pharmaceuticals.

The product can still generate attractive contribution margins under the right conditions because active pharmaceutical ingredient cost is not the sole determinant of price. However, low volume, compliance costs, specialized logistics, and product wastage can offset those margins.

Which companies are positioned to supply P-32 products?

The supply base is likely to include specialized radiopharmaceutical companies, nuclear pharmacies, hospital-based radiopharmacies, and regional distributors. Company-level attribution is difficult because products may be manufactured by one entity, distributed by another, and administered through a hospital or nuclear pharmacy.

The strongest commercial position would generally belong to companies with:

• Existing therapeutic radiopharmaceutical operations
• Reactor or isotope-production access
• National or regional distribution
• Radiation-licensed facilities
• Established hospital relationships
• Multiple radioisotope products

P-32 sodium phosphate alone is unlikely to justify a dedicated manufacturing platform. It is more economically viable as part of a broader portfolio.

Are there Paragraph IV challenges or biosimilar risks?

Paragraph IV litigation is unlikely to be a major current market issue. The product’s age, low commercial value, and limited patent protection reduce the incentive for a conventional generic challenger to invest in extensive litigation.

There is no biosimilar risk because sodium phosphate P-32 is a small-molecule radiopharmaceutical, not a biologic. Competitive substitution is more likely to occur through:

• Conventional generic cytoreductive medicines
• Newer branded hematology drugs
• Alternative radiopharmaceuticals
• Hospital-compounded or regional radiopharmacy products

Any generic-style entrant would still need to address radioactive-drug manufacturing, bioequivalence or pharmaceutical equivalence requirements, dose calibration, and licensed distribution.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible:

Continued niche supply

An incumbent maintains the product for selected hematology patients and institutions that value low cost and established clinical use. Pricing remains controlled, and volume gradually declines.

Regional or intermittent supply

Availability becomes dependent on isotope access, manufacturing schedules, or distributor economics. Hospitals may use P-32 only when other options are unavailable or unaffordable.

Product withdrawal and clinical substitution

A supplier exits because annual volume cannot support compliance and distribution costs. Treatment shifts to hydroxyurea, interferon, busulfan, ruxolitinib, or other alternatives.

The most likely long-term scenario is gradual contraction rather than a rapid commercial collapse, because legacy radiopharmaceuticals can persist in specialist settings after losing mainstream status.

What litigation and licensing issues affect the market?

No major current patent-litigation or licensing trend is central to sodium phosphate P-32. Commercial risk is operational rather than litigation-driven.

Potential contractual issues include:

• Isotope-supply agreements
• Reactor allocation contracts
• Nuclear pharmacy distribution arrangements
• Hospital purchasing agreements
• Regional licensing and handling permissions
• Technology-transfer arrangements for radiopharmaceutical preparation

A licensing transaction involving P-32 would more likely concern manufacturing capacity, distribution rights, or a broader radiopharmaceutical portfolio than exclusive rights to the active ingredient.

Key Takeaways

• Sodium phosphate P-32 is a therapeutic radiopharmaceutical, not an excipient.
• Its market is small, mature, and likely declining in developed healthcare systems.
• No reliable standalone public revenue or market-size series exists.
• Clinical use has been displaced by hydroxyurea, interferon, ruxolitinib, and other therapies.
• Patent protection is unlikely to provide meaningful current exclusivity.
• Supply-chain, isotope, licensing, and radiopharmacy capabilities are more important than patents.
• The product has no biosimilar pathway and limited Paragraph IV incentive.
• Financial value depends on portfolio integration and infrastructure reuse rather than P-32 sales alone.
• The residual market is concentrated in selected older, refractory, or resource-constrained patient populations.

FAQs

Is sodium phosphate P-32 an excipient in drug manufacturing?

No. Sodium phosphate P-32 is a radioactive active pharmaceutical ingredient used for therapeutic purposes. It should not be classified with nonradioactive phosphate excipients used as buffers, tonicity agents, or pH adjusters.

Does sodium phosphate P-32 have a patent cliff?

Its principal patent exposure is historical. The active compound is old, and current commercial competition is shaped more by regulatory authorization, isotope access, and radiopharmacy capability than by an imminent patent cliff.

Can a generic manufacturer launch sodium phosphate P-32?

A launch is technically possible but commercially difficult. The manufacturer would need an approved product, radioactive-material licenses, validated manufacturing, calibrated dosing, isotope supply, and specialized distribution.

Is P-32 sodium phosphate still used for polycythemia vera?

It may remain an option in selected patients, particularly older patients or those with limited alternatives. Modern treatment guidelines generally favor other cytoreductive strategies for many patients.

What is the main investment risk for a sodium phosphate P-32 supplier?

The main risk is volume erosion combined with fixed manufacturing and compliance costs. A supplier that lacks a broader radiopharmaceutical portfolio may find the product economically difficult to sustain.

References

1. International Atomic Energy Agency. (2009). Cyclotron produced radionuclides: Physical characteristics and production methods. IAEA.

2. Tefferi, A., Barbui, T., & others. (2024). Polycythemia vera and essential thrombocythemia: Treatment principles and contemporary management. American Journal of Hematology.

3. National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative neoplasms. NCCN.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. National Library of Medicine. (n.d.). DailyMed: Sodium phosphate P-32 injection labeling. https://dailymed.nlm.nih.gov/